Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2005 | 1 |
2006 | 1 |
2014 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for
fatemeh serial
Your search for
Fatemeh Serian
retrieved no results
Activity of liver enzymes in multiple sclerosis patients with Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention.
Complement Ther Med. 2014 Dec;22(6):986-93. doi: 10.1016/j.ctim.2014.10.004. Epub 2014 Oct 31.
Complement Ther Med. 2014.
PMID: 25453518
Clinical Trial.
There was no significant difference in the study parameters at baseline. Serum levels of liver enzymes (GGT, AST, and ALT) were serially monitored. Intervention was associated with liver function alteration in three groups. ...
There was no significant difference in the study parameters at baseline. Serum levels of liver enzymes (GGT, AST, and ALT) were serially …
Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
Rafii F, Park M, Novak JS.
Rafii F, et al.
Antimicrob Agents Chemother. 2005 Feb;49(2):488-92. doi: 10.1128/AAC.49.2.488-492.2005.
Antimicrob Agents Chemother. 2005.
PMID: 15673722
Free PMC article.
To compare mutations in the DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE) genes of Clostridium perfringens, which are associated with in vitro exposure to fluoroquinolones, resistant mutants were selected from eight strains by serial passage in the presen …
To compare mutations in the DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE) genes of Clostridium perfringens, which are asso …
Item in Clipboard
Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients.
Akhlaghi F, Patel CG, Zuniga XP, Halilovic J, Preis IS, Gohh RY.
Akhlaghi F, et al.
Ther Drug Monit. 2006 Feb;28(1):95-101. doi: 10.1097/01.ftd.0000189898.23931.3f.
Ther Drug Monit. 2006.
PMID: 16418701
Clinical Trial.
The study included 13 diabetic and 11 nondiabetic, stable, kidney-transplant recipients who were receiving a triple maintenance immunosuppressive regimen. Serial plasma samples were obtained predose and at regular intervals for 12 hours. ...
The study included 13 diabetic and 11 nondiabetic, stable, kidney-transplant recipients who were receiving a triple maintenance immunosuppre …
Item in Clipboard
Cite
Cite